Formosa Laboratories, Inc. · TWSE:4746
Formosa Laboratories — Investor Presentation (August 2026)
21 slides from Formosa Laboratories's investor presentation, Aug 14, 2026
Slide 1: August 14, 2026 TWSE 4746
August 14 , 2026 TWSE 4746 2026/8/13 1
Slide 2: Agenda
• 2026 up to July Operation Results • Business Strategy • Business Update 2026/8/13 2
Slide 3: Disclaimer
Disclaimer This material has been prepared by Formosa Laboratories Inc. (“Formosalab”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herei
Slide 4: Operation Results
Operation Results 2026/8/13 4
Slide 5: Consolidated Revenues 2026 up to July YoY -7%
Consolidated Revenues 2026 up to July YoY -7% 5,000 4,851 4,731 4,360 4,000 3,766 3,000 2,763 2,563 2,000 -7% 1,000 - 2022 2023 2024 2025 2025 up to July 2026 up to July Million NTD 2026/8/13 5
Slide 6: Revenues 2026 up to July YoY -7%
Revenues 2026 up to July YoY -7% Million NTD YoY Polymers 879 -8% Vit. D Derivatives 509 21% CDMO 371 44% Steroids 242 -34% Respiratory Agents 148 -52% Inflammation 147 104% Others 267 -30% Total 2,563 -7% 2026/8/13 6
Slide 7: Product Category
Product Category Polyermers Vit. D Derivatives CDMO Steroids Respiratory Agents Inflammation Anticancers Immunomodulator Others 9% 9% 6% 6% 13% 12% 2% 2% 3% 2% 7% 4% 3% 6% 2% 5% 4% 4% 6% 3% 6% 5% 4% 6% 6% 10% 9% 11% 6% 12% 9% 0% 1% 1% 11% 3% 14% 16% 12% 13% 10% 11% 19% 19% 20% 19% 17% 16% 33% 34% 36
Slide 8: 2026 1H Profitability
2026 1H Profitability EPS NTD 0.04 BV per share NTD 61.75 50% 44% 42% 42% 40% 40% 37% 30% 22% 20% 21% 20% 16% 14% 11% 10% 9% 3% 3% 0.2% 0% Gross Margin Operating Margin Net Margin 2026/8/13 8
Slide 9: 2025Q2~2026Q2 Profitability
2025Q2~2026Q2 Profitability 45% 43% 42% 41% 41% 40% 35% 28% 25% 25% 25% 25% 25% 23% 19% 17% 16% 16% 15% 15% 11% 5% 2% -1% -5% -15% -12% Net Operating Margin Operating Profit Income after Tax Operating Expenses 2026/8/13 9
Slide 10: Business Strategy
Business Strategy 2026/8/13 10
Slide 11: Integrated RD and Manufacturing
Integrated RD and Manufacturing - High quality GMP manufacturing - DS to DP one stop - Supply chain service management - ADC - Effective output to - Peptide fulfill demand CDMO Generic API - Formulation development - Clinical and commercial Injectable manufacturing - Product development and license-
Slide 12: Diversified Alliance to Explore Business Opportunity
Diversified Alliance to Explore Business Opportunity Biologics API ADC Injectable CDMO ADC Nano-tech HPAPI API ADC CDMO 2026/8/13 12
Slide 13: Expand Oversee Footprint and Market
Expand Oversee Footprint and Market 2026/8/13 13
Slide 14: Key Business
Key Business 2026/8/13 14
Slide 15: Key API Products
Key API Products • Improve throughput • Expand manufacture capacity • Stable supply chain Highlight • Polymer: Market share remains leading. • Vitamin D: New products have been gradually commercialized, contributing to revenue. • Steroid : Shipments remain growing. • Inflammation: stable contributin
Slide 16: Comprehensive CDMO Service-One Stop Shop
Comprehensive CDMO Service-One Stop Shop API/DS Labelling/ CMC Injectable Research Packaging/ Development Manufacturing Manufacturing Logistics • Stable CMO supply to originator in Japan, Europe, Australia, and US. New projects under discussion. • Formosa stably expands North American CDMO business.
Slide 17: One stop ADC services
Once stop ADC services Service scope • Linker-payload, Bioconjugation, and process development • ADC candidate screening platform • Scale-up manufacturing. ADC-DS new line completes validation. The new line can support upto commercial scale supply • Comprehensive analytic services ADC CDMO highlight
Slide 18: Injectable Plant Status
Injectable Plant Status • Authority inspection is ongoing • Cytotoxic line - TFDA: 2022Q2 completed - FDA: passed first FDA on-site GMP inspection held in July 2024 - EMA: passed first EMA on-site GMP inspection held in May 2025 - TMMDA: completed Turkish EMA on-site GMP inspection in September 2025
Slide 19: Self-development Injectable Products
Self-development Injectable Products ◆ Eribulin Injectable (Global market size USD 370 million, US Market USD 130 million, EU market USD 80 million, TW market NTD 450 million) Territory Status Taiwan Hospital listing keeps going. Turkey Licensing agreement signed, registration ongoing. EU Licensing
Slide 20: Self-development Injectable Products
Self-development Injectable Products Other self-development injectable products are ongoing - Anemia - Jointly develop the TLX-054 injectable with Easywell. - GLP-1 Products Semaglutide injection is the first product under development. The estimated global market size is approximately: Ozempic: USD
Slide 21: Q&A
Q&A 2026/8/13 21
Formosa Laboratories — Investor Presentation (August 2026) on 6ix